Biography:
Mr. Soonho Song obtained his bachelor's and master's degrees in biological sciences from KAIST (Korea Advanced Institute of Science and Technology), specializing in Drug Delivery Systems. He began his career as a researcher at Dong-A Pharmaceutical in Korea and later pursued an MBA in Health Sector Management (HSM) at Duke University in the United States. Subsequently, he has primarily worked in marketing roles for diabetes and other metabolic therapeutic areas at global pharmaceutical companies such as Eli Lilly, AstraZeneca, and Ferring Pharmaceuticals. Since 2023, he has led the Strategic Planning Department at Inventage Lab Inc.
Development of a novel long-acting semaglutide, IVL3021, and its physicochemical and pharmacokinetic studies